Broader access to costly Hep C drugs may yield few benefits for Pa. Medicaid, study finds

A new study that projects what could happen if Pennsylvania covered the costly treatment of hepatitis C for everyone in Medicaid yields some surprises for policymakers nationwide: Few lives would be saved. Some patients might actually fare worse. The federal government would likely reap savings, at the expense of the states. The counter-intuitive findings from the University of Pittsburgh may become part of pitched debates in state capitols and the incomi